Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data across its cardiovascular portfolio at the American Heart Association (AHA) Annual Scientific Sessions, taking place this week ...

and anticoagulant Xarelto (rivaroxaban), and BMS' blood thinner Eliquis (apixaban) are among the 10 medicines elected for the first round of Medicare price reductions, which are due to come into ...

ICER isn't officially involved in the price negotiations introduced under the Inflation Reduction Act (IRA), but contributed a "special report" on Bristol Myers Squibb and Pfizer’s Eliquis ...

A senior official of the Pharmexcil said drugs such as Merck's Pembrolizumab (Keytruda) whose revenue were at USD 25 billion and Bristol-Myers Squibb's Eliquis (Apixaban)-USD 12 billion, among others ...

Purpose The pharmacology, pharmacokinetics, efficacy, and safety of apixaban are reviewed. Summary Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid onset of action.

Medically reviewed by Femi Aremu, PharmD Borage is an herb from the Borago officinalis plant, which grows across the Middle ...

Bristol Myers Squibb’s robust cardiovascular portfolio and significant upcoming data presentations at the AHA meeting are positioning the company as a key player in the fight against cardiovascular ...